Jaime Bald

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof et al. · Blood · 2016 · 918 citations · Full text

Life Sciences, Immunology, Oncology +17

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Homer Adams, Frederik Stevenaert, Jakub Krejcik et al. · Cytometry Part A · 2018 · 160 citations · Full text

Medicine, Immunology, Pharmacology +16

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

Christopher R. McCudden, Amy Axel, Dominique Slaets et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2016 · 119 citations · Full text

Life Sciences, Immunology, Oncology +17

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

Tineke Casneuf, Homer Adams, Niels W.C.J. van de Donk et al. · Leukemia · 2020 · 117 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Christopher Chiu, Tineke Casneuf, Amy Axel et al. · Blood · 2016 · 45 citations

Life Sciences, Immunology, Oncology +16